The centralization of ethical reviews under Law 14.874/2024 aims to permanently eliminate the ‘re-review’ culture that has historically stalled large-scale clinical trials. This move marks a fundamental modernization of the Brazilian clinical research landscape, recently highlighted at the ‘Clinical Development in LATAM’ forum. Organized as a collaborative effort between the Ministry of Health and key regulatory bodies, the initiative sought to align domestic standards with international best practices. Historically, Brazil was perceived as a high-potential yet bureaucratically complex market, where unpredictable timelines deterred significant pharmaceutical investment. However, the current shift toward a streamlined, data-driven ecosystem has redefined the nation’s value proposition for global sponsors. By addressing systemic bottlenecks and administrative hurdles, Brazil is positioning itself as a premier destination for pharmaceutical innovation, ensuring it can handle a higher volume of complex trials while maintaining safety.
Accelerating Development Through Structural Regulatory Reform
Enhancing Review Speed and Operational Predictability
The implementation of RDC 945/2024 has fundamentally redefined the cadence of clinical trial approvals conducted by the Brazilian Health Regulatory Agency, known as ANVISA. A strict 90-day review ceiling is now the standard, providing a level of predictability that was previously unattainable for international pharmaceutical sponsors. This regulatory shift is anchored by a ‘silent approval’ mechanism, which allows sponsors to move forward with their clinical development if the agency does not provide a formal response within the mandated timeframe. This mechanism eliminates the threat of open-ended administrative delays, allowing Brazil to be seamlessly integrated into global development timelines. For sponsors, this means that the uncertainty of the past has been replaced by a transparent process that rewards early preparation and high-quality submissions. This newfound speed does not compromise the agency’s oversight but rather focuses its efforts on high-impact scientific evaluations.
The shift toward predictability is not merely an administrative convenience but a strategic asset that enhances the overall quality of clinical data collected within the region. Before these reforms were fully realized, the lack of clear timelines often forced sponsors to treat Brazil as a secondary site, often missing the window for inclusion in primary global filings. Now, with a standardized 90-day window, the country is increasingly becoming a primary choice for high-priority trials. The ability to forecast exactly when a study can begin allows for better coordination of logistics, patient recruitment strategies, and resource allocation. Experts at the recent forum noted that this new transparency has led to a surge in high-complexity trial submissions, particularly in oncology and rare diseases. Sponsors are now more willing to invest in sophisticated infrastructure within the country, knowing that their efforts will not be undermined by unforeseen regulatory delays that could jeopardize global timelines.
Strategic Resource Allocation and Global Standards
To maintain this accelerated pace, ANVISA has adopted sophisticated strategies such as regulatory reliance and risk-based assessments to optimize its internal resources. Regulatory reliance allows the agency to leverage technical evaluations already performed by recognized foreign regulatory authorities, such as the FDA or EMA, thereby avoiding the redundancy of re-evaluating established data sets. This collaborative approach does not mean a relaxation of standards; rather, it represents a more intelligent use of scientific expertise to focus on the unique aspects of a trial that specifically impact the local population. By utilizing these streamlined pathways, the agency can dedicate more time to assessing investigational products that address urgent public health needs or fill critical therapeutic gaps. This methodology ensures that the most innovative treatments reach the clinical testing phase faster, benefiting patients who may have limited options under traditional care protocols.
The successful navigation of these new pathways requires a proactive shift in how sponsors prepare their documentation and choose their regulatory strategies. Industry experts emphasize that early engagement with ANVISA and the utilization of prioritization categories are essential for maximizing the benefits of the current system. For instance, studies targeting life-threatening conditions or those involving pediatric populations are eligible for expedited review tracks that further compress the standard timelines. This strategic flexibility allows Brazil to respond dynamically to global health crises and emerging medical trends. Moreover, the integration of risk-based assessments means that lower-risk studies, such as those involving well-understood drug classes, undergo a more efficient review process, freeing up specialized personnel to handle the complexities of gene therapies and advanced biologics. This tiered approach has created a more resilient and scalable regulatory system.
Modernizing Ethical Oversight and Infrastructure
Centralizing Ethical Reviews for Maximum Efficiency
The centralization of ethical oversight for multicenter studies under Law 14.874/2024 has effectively removed one of the most significant historical barriers to research in Brazil. Previously, decentralized reviews led to conflicting queries and repetitive evaluations across various participating sites, often delaying trial starts by many months. The current mandate ensures that a single lead ethics committee handles the primary evaluation for a multicenter protocol. Other participating sites are now simply notified of the decision rather than being required to conduct their own exhaustive re-evaluations. This centralized model ensures that ethical standards remain uniform across the country, providing a consistent experience for both the sponsors and the patients participating in clinical trials. By reducing the administrative burden on individual institutions, the law allows investigators to focus on the scientific and clinical aspects of the research.
The tangible impact of these ethical reforms is clearly reflected in the data compiled throughout the first half of the current year. Analysis of over 500 pharmaceutical trials has shown that the median time for ethical review has plummeted to just 36 business days, a remarkable improvement from the 59-day average seen only two years ago. Furthermore, the efficiency and quality of these submissions have improved significantly, with over 80 percent of studies now receiving full approval within just one or two review rounds. This surge in productivity is largely attributed to the better professionalization of ethics committee members and the clear national guidance provided by the Instância Nacional de Ética em Pesquisa. By standardizing the requirements and providing a digital framework for communication, the government has minimized the administrative friction that previously discouraged investment. This reduction in lead time directly translates to faster patient enrollment and a quicker path to market.
Strengthening Site Readiness and Digital Systems
As regulatory and ethical hurdles are resolved, the Ministry of Health has focused its efforts on strengthening the operational capacity and infrastructure of research sites nationwide. This initiative includes a comprehensive mapping of existing infrastructure to identify areas for investment and specialized training for clinical staff. To ensure that site readiness matches the speed of regulatory approvals, the government is modernizing digital systems to replace aging platforms with more agile, integrated solutions. These upgrades are designed to simplify administrative tasks such as contract negotiations and logistics management, which often become the new bottlenecks when review times are shortened. By standardizing administrative workflows and investing in digital tools, Brazil ensures that its research centers can keep pace with the accelerated legal landscape. The result is a robust and reliable environment where innovation thrives and life-saving treatments move from the laboratory to the patient.
Complementing these physical infrastructure improvements is a major push for digital modernization within the clinical research ecosystem. Plans are currently underway to replace the aging ‘Plataforma Brasil’ with a more agile and integrated digital system that aligns seamlessly with the current legal framework. This new platform is designed to automate many of the administrative tasks that previously caused bottlenecks, such as contract negotiations, budget finalizations, and import logistics for investigational products. By streamlining these back-end processes, the Ministry of Health aims to ensure that the time gained during the regulatory phase is not lost during the operational startup phase. Standardization of institutional contracts has also become a priority, reducing the need for lengthy legal reviews at each individual site. These digital and administrative enhancements represent a holistic commitment to efficiency, ensuring that every step of the clinical trial lifecycle is optimized.
Establishing a Sustainable Research Ecosystem
The comprehensive reforms enacted within the clinical research sector successfully dismantled the historical barriers of bureaucracy and unpredictability. By establishing a firm 90-day regulatory ceiling and centralizing ethical reviews, the government provided a clear and competitive pathway for global pharmaceutical sponsors to bring innovation to the local market. These initiatives transformed Brazil into a more attractive destination for investment, as evidenced by the record-low review times and the increased volume of complex multicenter trials currently underway. Sponsors that already integrated these new timelines into their development strategies reported significant improvements in site activation speeds and overall project efficiency. Moving forward, the focus must shift toward maintaining these high standards through continuous professional training and the full implementation of modernized digital platforms. The ultimate success of this transformation depended on the sustained collaboration between the public sector and private industry to ensure that Brazil remained a reliable and high-quality partner in the global pursuit of medical advancement.
